RARA-WIPF2 fusion gene as well as application and detection kit thereof

• Main Authors: LU YING, WANG HAINA, YAN JINSONG
• Format: Patent
• Language: Chinese; English
• Published: 04.03.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention provides an RARA-WIPF2 fusion gene as well as application and a detection kit thereof. The sequence of the fusion gene is shown as SEQ ID NO. 1. The new fusion gene RARA-WIPF2 in acute myeloid leukemia is firstly found and identified, the abundance of the fusion gene is closely related to the disease progress stage, and the fusion gene can be used as a specific molecular marker of acute myeloid leukemia, so that a kit which can be clinically used for diagnosing and monitoring minimal residual disease (MRD) of a patient is developed. The kit uses Taqman probe real-time fluorescence PCR to carry out absolute quantification on the RARA-WIPF2 fusion gene in the body of an acute myeloid leukemia patient, the detection specificity is good, the sensitivity is high, the method is simple, convenient and efficient, the cost is low, and clinical diagnosis and treatment requirements can be met. 本发明提供一种RARA-WIPF2融合基因及其应用和检测试剂盒，所述融合基因序列如SEQ ID NO.1所示。本发明首先发现、鉴定了急性髓细胞白血病中存在新融合基因RARA-WIPF2，该融合基因丰度与疾病进展阶段密切相关，可以